(Camden, New Jersey) — The Cooper Cancer Institute has expanded its physician faculty with the appointment of Nancy L. Lewis, M.D. Nancy comes to Cooper from Fox Chase Cancer Center in Philadelphia, Pa., where she served as an Associate Member in the Genitourinary, Breast, and Gastrointestinal Malignancies Programs; Director of the Medical Residency and Sub-Intern Program; and as Associate Director of the Phase I Clinical Research Program.
Dr. Lewis will be responsible for developing the Phase I Clinical Research Program within the Cooper Cancer Institute. “Dr. Lewis will collaborate with pharmaceutical companies to expand the clinical research program at CCI,” said Generosa Grana, M.D., Director, Cooper Cancer Institute and Head of the Division of Hematology-Medical Oncology at Cooper University Hospital. “Through this program Cooper patients will have access to cutting-edge cancer treatments by participating in clinical trials of new agents in the early stage of their development.”
In Phase I trials, promising novel agents are tested alone or in combination with standard therapies. These studies are designed to assess the safety, tolerability, pharmacokinectics and pharmacodynamics of a drug or combination of drugs. Many of these newer agents offer the promise of greater efficacy and less toxicity when compared to standard chemotherapeutic treatments.
Dr. Lewis will also be an active member of the division’s clinical staff. She will focus her practice in caring for patients with advanced solid tumors, with a primary interest in gastrointestinal and genitourinary cancers.